Skip to Content

Esbriet (pirfenidone) Disease Interactions

There are 3 disease interactions with Esbriet (pirfenidone):

Moderate

Pirfenidone (Includes Esbriet) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Increases in ALT and AST (>3 x ULN) with or without concomitant elevations in bilirubin, have been reported in patients treated with pirfenidone. These findings were reversible with dose modification or treatment discontinuation. Conduct liver tests prior to therapy initiation in all patients, then monthly for the first 6 months and every 3 months thereafter. Dose modification or interruption may be necessary for liver enzyme elevations. Pirfenidone should be used with caution in patients with mild to moderate hepatic impairment, monitoring adverse reactions. The safety and efficacy of pirfenidone has not been studied in patients with severe hepatic impairment, and is not recommended for use in these patients.

Moderate

Pirfenidone (Includes Esbriet) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Pirfenidone should be used with caution in patients with mild, moderate, or severe renal impairment, monitoring for adverse reactions and considering dosage modifications or discontinuation as needed. The safety and efficacy of pirfenidone has not been studied in patients with end-stage renal disease requiring dialysis, so its use is not recommended in these patients.

Moderate

Pirfenidone (Includes Esbriet) ↔ Smoking

Moderate Potential Hazard, Moderate plausibility

Applies to: Smoking

Smoking causes decreased exposure to pirfenidone, which may alter its efficacy. Patients should be instructed to stop smoking prior to treatment, and to avoid smoking while taking pirfenidone.

Esbriet (pirfenidone) drug Interactions

There are 110 drug interactions with Esbriet (pirfenidone)

Esbriet (pirfenidone) alcohol/food Interactions

There is 1 alcohol/food interaction with Esbriet (pirfenidone)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide